{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:52:26Z","timestamp":1791305546475,"version":"4.3.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Drug-resistant tuberculosis (DR-TB) remains a major global public health challenge, while local drug resistance data in southwestern China are still incomplete. The drug resistance characteristics of\n                      <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                      (MTB) in the Liupanshui area have not been systematically reported, and the clinical application value of the high-resolution melting (HRM) method for drug resistance detection in this region also lacks evaluation evidence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      From February 2023 to September 2025, 1200 TB patients who attended designated TB treatment facilities in Liupanshui City were enrolled. The HRM method was used to detect resistance to isoniazid (INH), rifampicin (RFP), ethambutol (EMB), and fluoroquinolones (FQs). Meanwhile, among the culture-positive isolates (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 506), phenotypic drug susceptibility testing using the proportion method was performed for INH, RFP, EMB, levofloxacin (LVFX), and moxifloxacin (MOX). Univariate Chi-square tests and Cramer\u2019s V coefficient were employed to assess associations between clinical variables and drug resistance, and multivariate logistic regression was used to identify independent influencing factors for resistance. All effect estimates were supplemented with 95% confidence intervals (CIs). The Bonferroni method was applied for multiple testing correction, with three independent multiple comparison scenarios established in this study, and the corrected significance levels (\u03b1\u2019) were set at 0.0125, 0.01, and 0.0167, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among the 1200 patients, 67.6% were male, and 86.1% were newly treated. The HRM method detected resistance rates of 12.8% (95% CI: 11.1%\u201314.8%) for INH, 13.1% (95% CI: 11.3%\u201315.1%) for RFP, 5.4% (95% CI: 4.3%\u20136.8%) for EMB, and 2.4% (95% CI: 1.7%\u20133.4%) for FQs. For the proportion method (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 506), the resistance rates were 15.6% (95% CI: 12.9%\u201319.2%) for INH, 17.2% (95% CI: 13.3%\u201319.7%) for RFP, 9.9% (95% CI: 7.6%\u201312.8%) for EMB, 3.4% (95% CI: 2.1%\u20135.3%) for LVFX, and 1.8% (95% CI: 0.9%\u20133.3%) for MOX. The overall prevalence of multidrugresistant TB (MDR-TB) in the study population was 8.0% (95% CI: 6.6%\u20139.7%), with 7.3% (95% CI: 5.8%\u20139.0%) in newly treated patients and 12.6% (95% CI: 8.4%\u201318.5%) in retreated patients. Agreement between the HRM method and the proportion method was excellent for INH and RFP (Kappa: 0.93 [95% CI: 0.89\u20130.97] and 0.95 [95% CI: 0.92\u20130.98], respectively), moderate for EMB (Kappa: 0.62 [95% CI: 0.54\u20130.70]), and good for FQs (Kappa: 0.82 [95% CI: 0.74\u20130.90]). The positive predictive values of the HRM method for INH and RFP were 97.3% and 93.1%, respectively, and the negative predictive values were 98.4% and 99.8%, indicating excellent diagnostic performance. Regularity of treatment was strongly correlated with genetic resistance to all four drugs (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001, Cramer\u2019s V coefficient: 0.115\u20130.632), and retreatment was significantly associated with RFP genetic resistance (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001, Cramer\u2019s V coefficient: 0.133). Multivariate logistic regression analysis showed that irregular treatment was an independent risk factor for RFP resistance (odds ratio = 59.94, 95% CI: 34.78\u2013103.26,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The burden of DR-TB in Liupanshui area is substantial. The RFP resistance rate among newly treated patients (11.2%) exceeded the national baseline level for new cases. The prevalence of MDR-TB was relatively high, and retreated patients had a significantly elevated risk of resistance. The HRM method can serve as a rapid screening tool but should be complemented with phenotypic drug susceptibility testing for confirmation. Management of treatment adherence is a key element in controlling drug resistance. The findings of this study provide evidence-based support for the formulation of precise prevention and control strategies for TB in the Liupanshui area.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_105_26","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:00:28Z","timestamp":1790823628000},"page":"299-310","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Primary Drug Resistance Analysis of Mycobacterium tuberculosis in Liupanshui, China"],"prefix":"10.4103","volume":"15","author":[{"given":"Shunfu","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, The Third People\u2019s Hospital of Liupanshui, Liupanshui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1879-7102","authenticated-orcid":false,"given":"Ting","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Zhejiang Provincial People\u2019s Hospital Bijie Hospital (The First People\u2019s Hospital of Bijie), Bijie, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyou","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Third People\u2019s Hospital of Liupanshui, Liupanshui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Third People\u2019s Hospital of Liupanshui, Liupanshui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxu","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Blood Donation Service, Zhaotong Central Blood Station, Zhaotong, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojing","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Zhaotong Hospital of Traditional Chinese Medicine, Zhaotong, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Third People\u2019s Hospital of Liupanshui, Liupanshui, China"},{"name":"Department of Clinical Laboratory, Zhongshan Second People\u2019s Hospital, Zhongshan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"R2-20261006","first-page":"1","article-title":"WHO global tuberculosis report 2025: Key data analysis for the world and China","volume":"10","author":"He","year":"2025","journal-title":"Electron J Emerg Infect Dis"},{"key":"R4-20261006","doi-asserted-by":"crossref","first-page":"100522","DOI":"10.1016\/j.jctube.2025.100522","article-title":"Strengthening the global response to tuberculosis: Insights from the 2024 WHO global TB report","volume":"39","author":"Estaji","year":"2025","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"R5-20261006","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jgar.2024.05.018","article-title":"Prevalence and patterns of drug-resistant Mycobacterium tuberculosis in newly diagnosed patients in China: A systematic review and meta-analysis","volume":"38","author":"Jin","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"R6-20261006","doi-asserted-by":"crossref","first-page":"1697490","DOI":"10.3389\/fmicb.2025.1697490","article-title":"Drug resistance profile of Mycobacterium tuberculosis in China: Update until 2024","volume":"16","author":"Xu","year":"2025","journal-title":"Front Microbiol"},{"key":"R8-20261006","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.2147\/IDR.S423390","article-title":"Comparative study on tuberculosis drug resistance and molecular detection methods among different Mycobacterium tuberculosis lineages","volume":"16","author":"He","year":"2023","journal-title":"Infect Drug Resist"},{"key":"R9-20261006","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/ijmy.ijmy_21_24","article-title":"Rapid detection of M. tuberculosis and its resistance to rifampicin and isoniazid with the mfloDx\u2122 MDR\u2013TB test","volume":"13","author":"Ramasubban","year":"2024","journal-title":"Int J Mycobacteriol"},{"key":"R10-20261006","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00284-022-02960-z","article-title":"Detection of isoniazid and rifampin resistance in Mycobacterium tuberculosis clinical isolates from sputum samples by high-resolution melting analysis","volume":"79","author":"Parsa","year":"2022","journal-title":"Curr Microbiol"},{"key":"R11-20261006","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00284-023-03519-2","article-title":"Direct detection of fluoroquinolone resistance in sputum samples from tuberculosis patients by high resolution melt curve analysis","volume":"81","author":"Gupta","year":"2023","journal-title":"Curr Microbiol"},{"key":"R12-20261006","doi-asserted-by":"crossref","first-page":"101362","DOI":"10.1016\/j.lanmic.2026.101362","article-title":"Molecular diagnostic tests for isoniazid-resistant tuberculosis: A scoping review","volume":"7","author":"Nguyen","year":"2026","journal-title":"Lancet Microbe"},{"key":"R13-20261006","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/jgid.jgid_167_16","article-title":"Association of risk factors and drug resistance pattern in tuberculosis patients in North India","volume":"9","author":"Sinha","year":"2017","journal-title":"J Glob Infect Dis"},{"key":"R14-20261006","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3390\/tropicalmed7100300","article-title":"Mycobacterium tuberculosis drug resistance in Ethiopia: An updated systematic review and meta-analysis","volume":"7","author":"Reta","year":"2022","journal-title":"Trop Med Infect Dis"},{"key":"R15-20261006","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4103\/ijmy.ijmy_162_24","article-title":"Prevalence and temporal trends of multidrug-resistant tuberculosis in Iran from 1981 to 2023: A systematic review and meta-analysis","volume":"13","author":"Ayoubi","year":"2024","journal-title":"Int J Mycobacteriol"},{"key":"R16-20261006","doi-asserted-by":"crossref","first-page":"ofae416","DOI":"10.1093\/ofid\/ofae416","article-title":"Retreatment and anti-tuberculosis therapy outcomes in Brazil between 2015 and 2022: A nationwide study","volume":"11","author":"Barreto-Duarte","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"R17-20261006","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1186\/s12879-021-06708-1","article-title":"High resolution melting assay as a reliable method for diagnosing drug-resistant TB cases: A systematic review and meta-analysis","volume":"21","author":"Keikha","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R18-20261006","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.3390\/diagnostics12102307","article-title":"Combined locked nucleic acid probes and high-resolution melting curve analysis for detection of rifampicin-resistant tuberculosis in Northern Thailand","volume":"12","author":"Thant","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R19-20261006","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1128\/JCM.01264-13","article-title":"High-resolution melting curve analysis for rapid detection of rifampin resistance in Mycobacterium tuberculosis: A meta-analysis","volume":"51","author":"Yin","year":"2013","journal-title":"J Clin Microbiol"},{"key":"R20-20261006","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4103\/ijmy.ijmy_100_18","article-title":"Effective pragmatic approach of diagnosis of multidrug-resistant tuberculosis by high-resolution melt curve assay","volume":"7","author":"Negi","year":"2018","journal-title":"Int J Mycobacteriol"},{"key":"R21-20261006","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1080\/1061186X.2020.1853733","article-title":"Mycobacterial ethambutol responsive genes and implications in antibiotics resistance","volume":"29","author":"Xiang","year":"2021","journal-title":"J Drug Target"},{"key":"R22-20261006","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4103\/ijmy.ijmy_101_23","article-title":"Whole-genome sequencing reveals genotypic resistance in phenotypically susceptible Mycobacterium tuberculosis clinical isolates","volume":"12","author":"Hasan","year":"2023","journal-title":"Int J Mycobacteriol"},{"key":"R23-20261006","doi-asserted-by":"crossref","first-page":"1019198","DOI":"10.3389\/fpubh.2022.1019198","article-title":"Transmission of multidrug-resistant tuberculosis in Beijing, China: An epidemiological and genomic analysis","volume":"10","author":"Yin","year":"2022","journal-title":"Front Public Health"},{"key":"R24-20261006","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.2147\/IDR.S263082","article-title":"Genotypic distribution and a potential diagnostic assay of multidrug-resistant tuberculosis in Northern Thailand","volume":"13","author":"Anukool","year":"2020","journal-title":"Infect Drug Resist"},{"key":"R25-20261006","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/jgid.jgid_309_21","article-title":"Laboratory cost analysis of conventional and newer molecular tests for diagnosis of presumptive multidrug-resistant tuberculosis patients","volume":"14","author":"Yadav","year":"2022","journal-title":"J Glob Infect Dis"},{"key":"R26-20261006","first-page":"23","article-title":"Analysis of drug resistance and influencing factors in pulmonary tuberculosis patients aged 65 and above from 2020 to 2023","volume":"47","author":"Chen","year":"2025","journal-title":"Chin J Antituberc"},{"key":"R27-20261006","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev-pharmtox-041921-074800","article-title":"Emerging therapeutics, technologies, and drug development strategies to address patient nonadherence and improve tuberculosis treatment","volume":"62","author":"Garcia-Cremades","year":"2022","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R28-20261006","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.3390\/ijms24065202","article-title":"Tuberculosis: Pathogenesis, current treatment regimens and new drug targets","volume":"24","author":"Alsayed","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R29-20261006","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1186\/s12879-026-13156-2","article-title":"Cohort evaluation of an all-oral shorter regimen for drug-resistant tuberculosis in Ecuador","volume":"26","author":"Chac\u00f3n","year":"2026","journal-title":"BMC Infect Dis"},{"key":"R30-20261006","doi-asserted-by":"crossref","first-page":"638990","DOI":"10.3389\/fcimb.2021.638990","article-title":"Relapse or re-infection, the situation of recurrent tuberculosis in Eastern China","volume":"11","author":"Shao","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"R31-20261006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ijmy.ijmy_217_22","article-title":"Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review","volume":"12","author":"Putra","year":"2023","journal-title":"Int J Mycobacteriol"},{"key":"R32-20261006","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s12879-025-11067-2","article-title":"Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: A systematic review and meta-analysis","volume":"25","author":"Hu","year":"2025","journal-title":"BMC Infect Dis"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_105_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:02:47Z","timestamp":1791302567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_105_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_105_26","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-05-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}